The short version
Radiation therapy kills prostate cancer cells by damaging their DNA past the point where they can repair it. For localized disease at Grade Group 2 with adverse features, it's the other primary path alongside surgery. Long-term cancer control between the two is broadly equivalent. The differences are everything else — how you receive it, when side effects show up, what gets monitored after, and what salvage looks like if it fails.
“Radiation” isn't one thing. It's a family of modalities that differ in where the radiation comes from (outside the body vs. inside the gland), how it's shaped (beam geometry, dose conformity), and how many sessions it takes to deliver the prescribed dose. The right modality depends on disease characteristics — and on the patient.
How external beam radiation actually works
External beam radiation therapy (EBRT) uses a linear accelerator — a machine that produces high-energy X-ray (photon) beams aimed at the prostate from outside the body. Modern delivery is computer-shaped to conform tightly to the gland and avoid nearby organs (the rectum behind, the bladder above, the femoral heads to the sides).
Before treatment starts: a CT-based simulation maps the anatomy, fiducial markers (tiny gold seeds) are placed in the prostate so the beam can re-align to the gland's exact position at each session, and a treatment plan is computed by physicists and the radiation oncologist. A small rectal spacer (SpaceOAR) is often placed to push the rectum a few millimeters away from the prostate, reducing rectal dose during treatment.
Each daily session takes 10–20 minutes on the table. The radiation itself is invisible, painless, and over in a couple of minutes. Image guidance (cone-beam CT or fiducial-based tracking) repositions the patient before every beam.
The modalities
Within EBRT, the spread is mostly about how few sessions can deliver the prescribed dose without unacceptable side effects:
The historical standard. Daily small doses over two months, shaped by Intensity-Modulated Radiation Therapy (IMRT) or its faster cousin Volumetric Modulated Arc Therapy (VMAT, which delivers the beam continuously as the gantry rotates). Long course, very smooth side-effect curve.
Larger daily doses, fewer sessions. Modern evidence shows non-inferiority to conventional fractionation with similar side effects. Increasingly the EBRT default for localized disease.
Stereotactic Body Radiation Therapy condenses the whole course into five large-dose sessions. Real-time tracking compensates for prostate motion between heartbeats and breathing. Outcomes for low- and intermediate-risk disease look comparable to longer courses; favored when calendar burden matters and where the disease profile fits.
Uses proton particles instead of X-rays. Protons deposit most of their energy at a precise depth (the Bragg peak) and stop, which in principle spares tissue beyond the target. For prostate cancer specifically, head-to-head outcome evidence vs. photon IMRT/VMAT is thin; large randomized trials are ongoing. Available at limited centers; more expensive.
Tiny radioactive seeds (iodine-125 or palladium-103) are implanted directly into the prostate through the perineum under anesthesia, with ultrasound guidance. They deliver dose continuously over weeks to months as they decay; the seeds remain permanently. Highest dose to the gland, sharpest fall-off outside it. Best for low- and favorable-intermediate-risk disease where the gland anatomy fits.
Thin catheters are placed into the prostate through the perineum, and an iridium-192 source is robotically advanced through each catheter for minutes at a time to deliver a high dose, then withdrawn. The catheters come out. No permanent radioactivity. Often used as a boost combined with a shorter EBRT course in higher-risk disease.
An EBRT course covers a wider field (catches potential microscopic extension and adjacent tissue), with a brachytherapy boost adding a higher dose directly inside the gland. Used for unfavorable intermediate, high, and very-high-risk disease. The most aggressive radiation regimen, with side-effect profile to match.
ADT — the often-added piece
Androgen deprivation therapy (ADT) lowers testosterone to near-zero. Prostate cancer cells use testosterone as fuel, so ADT both slows the disease directly and makes the remaining cells more vulnerable to radiation. For unfavorable-intermediate, high-risk, and very-high-risk disease, ADT added to radiation improves long-term outcomes — that part is well-established by randomized trials.
Course length scales to risk:
- Favorable intermediate: usually no ADT.
- Unfavorable intermediate: short-course ADT, typically 4–6 months.
- High and very-high risk: longer course, typically 18–36 months.
Where I land on that scale is exactly what's unsettled — my case sits on the favorable/unfavorable intermediate line, so whether ADT is added at all is still an open question (more in the radiation analysis).
ADT comes with real side effects: hot flashes, fatigue, loss of libido, erectile dysfunction (which compounds the radiation's own ED risk), muscle loss, bone-density loss, mood changes, metabolic shifts. Most of these reverse after the course ends, but recovery is slower with longer courses and at older ages. ADT is not a small addition — it's the part of the radiation conversation that most patients underestimate.
Recovery & side-effect profile
Acute (during and just after treatment)
- Fatigue. Builds across the course, peaks late, resolves over weeks.
- Urinary symptoms. Urgency, frequency, weaker stream, sometimes burning. Usually improves over 1–3 months after treatment ends.
- Bowel symptoms. Urgency, looser stools, occasional blood. Spacer placement (SpaceOAR) materially reduces this. Most acute symptoms resolve.
- Sexual function. Initially fairly preserved — the ED curve with radiation is gradual, not sudden like with surgery.
Late (months to years after)
- Erectile dysfunction. Erections often decline gradually over 1–3 years post-treatment. Roughly half of previously potent men have meaningful long-term ED.
- Urinary irritation. Low-grade chronic frequency or urgency in a minority.
- Bowel changes. Mild chronic urgency or occasional rectal bleeding in a minority. Severe late toxicity is rare with modern technique.
- Stricture risk. Narrowing of the urethra or anastomotic area — uncommon but real.
- Secondary cancer risk. Small absolute increase in the long term (bladder, rectum) — relevant for younger patients with very long expected survival.
What radiation doesn't do
It leaves the prostate in place. That means no surgical pathology after treatment — no full-gland section to definitively answer the EPE, margin, seminal-vesicle, and lymph-node questions. The disease “answer” under radiation has to come from PSA behavior over time.
After radiation, PSA falls over months to a year, reaching a nadir (the lowest point). A small temporary bump can occur (“PSA bounce”) before settling back down — not a sign of failure. Biochemical recurrence after radiation is defined as PSA rising 2 ng/mL above the nadir.
If the disease comes back after radiation, salvage options narrow. Salvage prostatectomy is technically possible but harder than primary surgery — tissue planes are scarred, continence and erectile outcomes are worse, and complication rates are higher. Salvage radiation (a second course) is generally not possible. ADT or focal treatments become the main options. This is the inverse of the surgery path, where salvage radiation after surgery is well-established.
What I still want to know before deciding
Both radiation oncologists I consulted proposed short-course radiation; the specifics still to pin down:
- Which modality the radiation oncologist would actually recommend for my specific disease profile — and which they'd put second.
- Whether ADT would be added, for how long, and what side effects to expect on top of radiation alone.
- How the local radiation centers compare on technique, image guidance, and reported outcomes — same as with surgeons, the operator and the equipment matter.
- Whether genomic testing changes the radiation recommendation (Decipher and Artera can shift radiation/ADT decisions) — the last input still pending.
- SpaceOAR placement — standard at the institutions being considered?
- The specific monitoring schedule after treatment: PSA cadence, when imaging gets repeated, what triggers escalation.
This page is the radiation overview. The companion page, Radiation Therapy Analysis, takes these modalities and applies them to my specific biopsy findings — Grade Group 2 with cribriform and IDC-P, three positive containers on the right side, capsular abutment at the right mid PZPL — to narrow which modality fits, whether ADT is on the table, and what the radiation path looks like in detail.
Both paths drawn. The choice still to come.